We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Xcounter | XCT | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 275.00 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 275.00 |
| Top Posts |
|---|
Posted at 08/7/2011 07:46 by troutisout troutisout - 7 Jul'11 - 15:06 - 15 of 21 editRight I have gone back over ADVFN's info and have come up with this, LID EV/Sales 28.18/6.24......4.52 DEMG EV/Sale 35.41/6.28......5.64 ASD EV/Sales 259.84/101.68...2.56 - PE 45 ODX EV/Sales 13.5/7.9........1.71 - PE 155 MDW EV/Sales 3.06/10.48......0.29 - PE 14.08 AOR EV/Sales 4/1.36..........2.94 LMT EV/Sales 30.48/3.01.....10.13 XCT EV/Sales 8.13/3.1........2.62 TSTL EV/Sale 14.25/8.76......1.63 - PE 12 SUN EV/Sales 39/7.05.........5.53 - PE 21.61 Well from the table above we can see some wild differences in each valuation factor. Using ASD as an example (as we know what a comnpetitor was prepared to offer) it doesn't seem to have been the PE ratio that it was worked from, the Ev/sales figure of 2.56 looks to be in the centre of the range. so are EV/Sales the best way to look at value, certainly with so many not actually in profit PE and PEG are out the window. I would like to look more into forecast PEs but will need to see broker forecasts if there are any on some of the above shares, if anyone can post a link to any forecasts for any of the above, it will be greatly appreciated. Come and add any facts you can on these and any other smallcap medical equipment companies, |
Posted at 27/4/2011 07:35 by fineart333 RNS Number : 5173F XCounter AB 27 April 2011 PRESS RELEASE Stockholm, 27 April 2010 Result of Annual General Meeting and Board Update XCounter AB (AIM: XCT) ("XCounter"), a technology leader in the development of photon counting X-ray detectors and tomosynthesis based 3D medical imaging, held its Annual General Meeting yesterday in Stockholm. The resolutions to amend the Company's articles of association, the resolution to carry out a share consolidation, the resolution to approve the Company's de-listing and the resolution to authorise the board to issue shares were not passed by shareholders, as they did not achieve the requisite majority of two thirds of votes cast in favour. The resolution re-electing the members of the board was duly passed by shareholders, however, Yngvar Hansen-Tangen chose not to be re-elected and resigns from the Board with immediate effect. All other resolutions proposed were duly passed by the shareholders. Consequently, the Company will not presently proceed with the proposed de-listing from AIM, the listing on the NASDAQ OMX First North market in Stockholm and the share consolidation. Additionally, a group of minority shareholders requested a special investigation pursuant to chapter 10 section 21 of the Swedish Companies Act to look into certain defined aspects of the company's operations. The request gives shareholders the right to require the appointment of a person by the Swedish authorities (Lansstyrelsen) to investigate such aspects. The Company will make further announcements as necessary. For further information, please contact: XCounter AB Tel: +46 (0) 8 622 23 00 Mikael Strindlund, CEO Nomura Code Securities Tel: +44 (0) 20 7776 1200 Phil Walker Capital MS&L Tel: +44 (0) 207 307 5330 Mary Clark/Anna Davies About XCounter AB XCounter AB is a leader in the development of photon counting detector and tomosynthesis-based 3D medical imaging technology. For more information, please visit: www.xcounter.se This information is provided by RNS The company news service from the London Stock Exchange END |
Posted at 12/5/2010 07:30 by fineart333 RNS Number : 7611L XCounter AB 12 May 2010 ? XCounter PRESS RELEASE Stockholm, 12 May 2010 XCounter AB and Artemis Imaging GmbH sign agreement to develop innovative 3-D breast imaging system XCounter AB (AIM: XCT) ("XCounter"), a technology leader in the development of photon counting X-ray detectors and tomosynthesis-based 3D medical imaging, and Artemis Imaging GmbH ("Artemis"), have today signed a conditional agreement (the "Agreement") for the development and delivery of an innovative 3-D mammography CT system. The new breast imaging system will incorporate XCounter's innovative digital photon counting solid state detector platform, which enables fast, high quality 3-D imaging with the lowest possible radiation dose. Artemis aims to develop, validate and perform clinical evaluation ofa dedicated low-dose 3-D X-ray computed tomography (CT) scanner for the female breast. The breast CT system shall provide very high 3D spatial resolution of about 100 µm, yet work at dose levels comparable to today's standard, bi-plane digital mammography. As superposition-free CT imaging is provided, performance is expected to exceed that of mammography significantly with respect to sensitivity and specificity. According to the Agreement, Artemis will fund XCounter's Mammo CT detector development costs including a first delivery of a fully functioning prototype to secure exclusivity for the detector system. The Agreement is conditional upon Artemis finalizing full funding of the project. A significant portion of the funding is already secured. Professor Willi Kalender, CEO of Artemis Imaging GmbH, said: "XCounter has proven that its solid state photon counting detector technology fulfils all the requirements for Artemis' revolutionary, dedicated breast CT system which combines superb image quality with lowest possible radiation dose, which are crucial for this application. The performance characteristics of the technology will surpass all other existing approacheson the market. I am confident that we can secure the remaining balance of the financing required for this project and I look forward to working with XCounter on this development." Mikael Strindlund, CEO of XCounter, said: "This is a true breakthrough for patients and for XCounter. The cutting edge technologies from AJAT and XCounter offers state of the art solid detector and photon counting enabling fast, high quality 3-D imaging with lowest possible radiation dose. This agreement confirms our leading position in photon counting detection technology. We are looking forward to developing this project, and other potential imaging projects with Artemis." This agreement follows on from a collaboration announced in 2009, in which Artemis reviewed the potential for the XCounter technology in developing a new detector. The agreement is further validation of the potential medical applications of XCounter's technology. For further information, please contact: XCounter AB Tel: +46 (0) 8 622 23 00 Mikael Strindlund, CEO Nomura Code Securities Tel: +44 (0) 20 7776 1200 Phil Walker/Clare Terlouw Capital MS&L Tel: +44 (0) 207 307 5330 Mary Clark/Anna Davies This information is provided by RNS The company news service from the London Stock Exchange END AGRKMGMKKZZGGZG |
Posted at 17/3/2010 16:42 by buystock dubois i have over 500k of these this is my favourite stock by a country mile.average 6.7p.it has all the makings of a major player but is way overlooked.3dt mammo scan partnership with artemis should come on the 25th along with a 2.8m grant artemis applied for from the german government.fully funded pr-xmas and instutions loading up.no 1 trick pony go to AJAT OY OUR FINNISH COMPANY.JUST PUT A NEW PRODUCT ON THE MKT FOR dental use.£24k a hit plus maintainance they are going of the production line like hotcakes + ndt radiography for pipe welds in norwegian sector.thats enough for now .THE NEW /ajat art cdt sensor now on sale through f1fimet. IntraOS 70 - intra-oral x-ray unit for traditional and digital pictures; wall mounted, 70kV, short/medium/long arm page 1Subsidiary signs major development agreement page 2 £1,850.00 IntraOS 70 - intra-oral x-ray unit for traditional and digital pictures; mobile, 70kV page 1 page 2 £1,950.00 IntraOS 70 DG - intra-oral x-ray unit designed specifically for digital images - 0.4 focal spot; wall mounted brochure £TBA extra-oral OPG (traditional) PantOS 16 Xp - traditional OPG brochure £10,490.00 PantOS 16 Xp Ceph - traditional OPG with cephalometric arm £12,990.00 extra-oral OPG (digital) PantOS Dg Xp - digital OPG brochure £16,990.00 NEW PantOS Dg Xp Ceph - digital OPG with cephalometric arm, product launched at the International Dental Show 2009 in Cologne, unbeatable price for a digital, panoramic x-ray unit with cephalometric arm, image size: panoramic 3580 x 1535 pix, ceph 5300 x 4608 pix brochure £24,990.00 25th draws close.WHITEHORSE CAPITAL TOOK 11% IN DEC 2009 .and probable grant news due on the 26th january a bonus as we are now fully funded.wait for the A.A BUY.Co-development of the breast CT scanner provides a cost effective way for XCounter to progress the development of the detector technology as, under the current proposals, Artemis intends to provide 1.75m over a period of two years during the R&D phase of the project. Artemis would fund XCounter's detector development in return for exclusivity for the PCT technology in the Mammo CT application. Artemis has applied for a 2.8m grant from the German government (Bundesministerium für Bildung und Forschung) to fund half of the project. It is currently anticipated that the German government will announce the results of the grant application on or around 26 January 2010. If Artemis' application for the grant is successful, the Company anticipates negotiating and signing a co- development agreement with Artemis in the first quarter of 2010 which will include provisions granting Artemis exclusivity for the PCT technology for the Mammo CT application. Following the developmental phase, Artemis proposes to licence the product to a major OEM and it is XCounter's current intention at that time to enter into a supply agreement with Artemis, so as to exclusively manufacture and supply the detector components to be integrated into the completed Mammo CT device. The Directors believe that the total initial market for the complete Mammo CT systems to be 150m per annum. 21 Posts: 804 margic21 Answer Opinion: Strong Buy Price: 6.00 artemis..4 Mar '10 was on the phone to a member of staff today... been in contact via email... they say there application has taken longer as it has been viewed as a business loan as opposed to a grant... however, although they will not release and price sensitive information they did comment... ' Mr ioannou (me).. we believe we will get the result we had expected before considering any form of application, and will be informing all relevant associates of our plans once we have received official conformation.. we expect to be working closer to the mention company (xct) within 2 weeks and possible much sooner.' i could only buy 25 thousand shares and as you can see they have yet to appear on any market.. but are in my account and im now very excited.. i soon expect to see a news release or two followed by a re-rating within 3 months... for me this is a huge multi-bagger and i dont often set a recommendation on a stock.. but i cannot believe this is falling under the radar... but happy to be invested and see 30p a easy target short term.... people will be missing this one |
Posted at 08/3/2010 15:57 by buystock XCT -3T Tomosynthesis - Product Pipeline XCounter has submitted a total of 54 patent families. The patents cover completely new sensing technologies that are substantially different from those used in today's traditional medical X-ray technologies. The XC Mammo -3T is the first system in a pipeline of devices planned to commercially exploit the XCounter technology. Deployment of the XC Mammo -3T into the clinic will complete a key step toward targeting other imaging applications in whole-body imaging, as well as imaging support for therapy and interventional procedures. The XCT -3T technology has the potential to impact the medical imaging market via complementary and improved diagnostic tools and early, proactive clinical examinations for cancer, stroke and heart disease. Also, future XCT -3T-based systems may have the potential to expand the pre-symptomatic screening market to include not only 3D mammography (digital breast tomosynthesis), but also lung, colon, prostate, whole-body and cardiac screening. Our patents protect a series of product pipelines beyond the product platforms presently prioritised. Also, the patents do not only cover new sensing technologies in medical imaging, they also cover new application areas outside medical imaging made possible by our proprietary technology. |
Posted at 08/3/2010 15:52 by buystock GOZ ADDED TODAY will be accumulating as much as possible.Subject: BUY 30000 XCT executed @ 6.20 GBX March 08, 2010 09:03 AM UK Your Market order xxxxxxxxx to BUY 30000 XCT (Xcounter AB) has been executed at 6.20 GBX |
Posted at 25/1/2010 14:19 by buystock 26th jan news close XCT -3T Tomosynthesis - Product Pipeline XCounter has submitted a total of 54 patent families. The patents cover completely new sensing technologies that are substantially different from those used in today's traditional medical X-ray technologies. The XC Mammo -3T is the first system in a pipeline of devices planned to commercially exploit the XCounter technology. Deployment of the XC Mammo -3T into the clinic will complete a key step toward targeting other imaging applications in whole-body imaging, as well as imaging support for therapy and interventional procedures. The XCT -3T technology has the potential to impact the medical imaging market via complementary and improved diagnostic tools and early, proactive clinical examinations for cancer, stroke and heart disease. Also, future XCT -3T-based systems may have the potential to expand the pre-symptomatic screening market to include not only 3D mammography (digital breast tomosynthesis), but also lung, colon, prostate, whole-body and cardiac screening. Our patents protect a series of product pipelines beyond the product platforms presently prioritised. Also, the patents do not only cover new sensing technologies in medical imaging, they also cover new application areas outside medical imaging made possible by our proprietary technology. |
Posted at 16/1/2010 07:45 by buystock all loading up Changes in significant shareholdingsTIDMXCT RNS Number : 6760F XCounter AB 15 January 2010 PRESS RELEASE Stockholm, 15 January 2010 XCounter notification of changes in significant shareholdings XCounter AB (AIM: XCT) ("XCounter"), a technology leader in the development of photon counting X-ray detectors and tomosynthesis based 3D medical imaging, announces today that it has received notification from XR Invest AS that it has purchased 11,818,181 XCounter shares representing 13.05 % of the issued share capital of XCounter. Stockholm, 03 December 2009 XCounter notification of changes in significant shareholdings XCounter AB (AIM: XCT) ("XCounter"), a technology leader in the development of photon counting X-ray detectors and tomosynthesis based 3D medical imaging, announces it has received notification from Whitehorse Investing Ltd ("Whitehorse") that it has purchased 4,100,000 XCounter shares representing 9.41 % of the issued share capital of XCounter, from HealthCap. The Company has also received notification that funds managed by HealthCap RNS Number : 5924E XCounter AB 22 December 2009 PRESS RELEASE Stockholm, 22 December 2009 XCounter notification of changes in significant shareholdings XCounter AB (AIM: XCT) ("XCounter"), a technology leader in the development of photon counting X-ray detectors and tomosynthesis based 3D medical imaging, announces today that it has received notification from Whitehorse Investing Ltd ("Whitehorse") that on the 21st December 2009 it purchased 734,786 XCounter shares taking its total shareholding to 4,834,786 shares which represents 11.1 % of XCounter. |
Posted at 29/12/2009 13:47 by buystock XCounter AB XCounter has developed a completely novel technology, called XCT, for digital X-ray imaging, which counts each individual X-ray. The Company, founded in 1997 and located in Danderyd, is developing applications for low radiation dose 2D and 3D imaging based on the XCT platform. XCT is deemed to have the potential to become the future gold standard for most X-ray imaging systems, in addition to enable novel diagnostic tools. Digital X-ray camera with its high resolution/low dose characteristics is primarily for medical applications, but also for industrial applications such as non-destructive testing. Vision XCounter's vision is to become the innovation house of choice in X-ray detection technologies integrated with the world's leading manufacturers. Web Address www.xcounter.se Senior Investment Manager Ola Romney +46 (0)8 763 79 13 ola.romney@seb.se Back Close Skandinaviska Enskilda Banken AB (publ) Contact us |
Posted at 29/12/2009 13:33 by buystock About XCounterXCounter is an innovation and development house for the leading X-ray companies. XCounter offers ready-to-market imaging systems based on unique 3D technologies. The Company was founded in 1997 by researchers with NASA and CERN experience in space research. It is listed on the London Stock Exchange's AIM market. XCounter is based in Stockholm, Sweden. XCounter's unique and proprietary technology for 3-dimensional X-ray imaging, XCT -3T, has a number of advantages over competing technologies. XCT -3T enables fast acquisition of high resolution 3D images, at low levels of radiation dose. This means more predictable diagnosis as well lower risks for the patients when compared to existing imaging techniques. XCounter currently has four product platforms in development based on XCT -3T, XCounter's unique technology. The first is XC Mammo -3T, the only system originally designed for 3D breast cancer screening. Secondly the XC MP -3T for general body imaging, which is introducing low dose 3D imaging in to general X-ray imaging and preventive cancer screening. Building on the existing technology which it has developed for XC Mammo -3T, XCounter is also developing two platforms for preventive cardiac imaging. XC Cardio -3T for functional imaging of the heart which will have the capability of imaging the perfusion of blood through the heart muscle, leakage through the valves and blood flow through coronary arteries in different phases of the heart cycle. These capabilities will give information enabling the doctor to take medical measures before any serious complications occur. The heart is a very dynamic organ, and many of the heart diseases are best visualized dynamically and our product platform XC Cardio -4T seeks to introduce a totally new dimension by imaging 3D movies of the beating heart. We believe XC Cardio -4T is a solution to a medical need, which none of the leading X-ray companies to date has been able to satisfactorily address. The XCT -3T based product platforms described above address the major part of the US$7 billion digital X-ray system market, and have the potential to expand the market through the introduction of novel low-dose screening applications. More information and our press releases can be accessed at www.XCounter.se. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
